LIXTE Biotechnology Holdings has filed its Annual Report on Form 10-K for the year ended December 31, 2025, documenting a period of substantial progress across clinical development, strategic expansion, and financial strengthening. The company advanced development of its lead compound LB-100, expanded clinical trials with additional sites and increased enrollment, completed the acquisition of Liora Technologies Europe Ltd. to enhance its cancer treatment platform, and raised more than $11 million to strengthen its balance sheet.
The clinical-stage pharmaceutical and med-tech company focuses on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that LB-100, its lead compound and first-in-class lead clinical PP2A inhibitor, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on published preclinical data, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer.
This compound represents part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. LIXTE’s novel approach is covered by a comprehensive patent portfolio, with proof-of-concept clinical trials currently in progress for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer and Advanced Soft Tissue Sarcoma. Additional information about the company's research and development can be found at https://www.lixte.com.
Through LIXTE’s wholly owned subsidiary, Liora Technologies Europe Ltd., the Company also is pioneering the development of electronically controlled proton therapy systems for treating tumors in various types of cancers. Liora’s proprietary flagship technology, LiGHT System, is believed to provide significant advantages over currently available technologies for treating tumors with proton therapy. This strategic acquisition expands LIXTE's technological capabilities and treatment modalities in the oncology space.
The financial implications of the reported developments are significant, with the company raising more than $11 million to strengthen its balance sheet. This capital infusion supports continued research and development efforts as LIXTE positions for continued growth and innovation in oncology. The filing of the Form 10-K provides investors and stakeholders with comprehensive documentation of these achievements and the company's strategic direction.
For the broader oncology field, LIXTE's progress with LB-100 represents potential advancement in cancer treatment approaches. The compound's mechanism of action as a PP2A inhibitor working through activation lethality could offer new therapeutic options for difficult-to-treat cancers. The expansion of clinical trials and increased enrollment suggests growing confidence in the compound's potential and moves the treatment closer to potential regulatory review and commercialization.
The integration of Liora Technologies Europe Ltd. adds proton therapy capabilities to LIXTE's portfolio, potentially creating synergies between pharmaceutical and medical technology approaches to cancer treatment. This diversification could enhance the company's value proposition and provide multiple pathways for addressing different cancer types and treatment scenarios. The combined approach of novel drug development with advanced radiation therapy technology positions LIXTE at the intersection of two important cancer treatment modalities.
